Sonya Del Tredici and John Keenan
Sonya Del Tredici and John Keenan
34. 24 mg of Buprenorphine
34. 24 mg of Buprenorphine
34. 24 mg of Buprenorphine
Monday 18th December 2023
Join Drs. Del Tredici and Keenan as they discuss buprenorphine dosing, Rite Aid's bankruptcy, and the FDA's menthol cigarette ban in this episode.
24 minutes
Informative
Empowering
Hopeful
Transformative
Supportive
About this podcast
Author:
Sonya Del Tredici and John Keenan
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Navigating Intimate Relationships
Family Recovery from Addiction
Nutritional Pathways to Recovery
Episodes:
56 (View all)
Do you want to link to this podcast?
Get the buttons here!Buprenorphine Dosing: Tackling Opioid Addiction in the Fentanyl Era
Episode Overview
- The episode discusses the prescribing of 24 mg of buprenorphine daily and its implications
- Examines Rite Aid's bankruptcy and the FDA ban on menthol cigarettes
- Explores a recent JAMA Network Open article comparing 16 to 24 milligrams of buprenorphine
- Highlights the benefits and considerations of higher buprenorphine doses in treating opioid use disorder
- Emphasizes the importance of staying informed about the latest research and insights
My patients are similar to those in this study. The treatment is feasible. I do prescribe 24 milligrams. The benefit is good. Retention in treatment, that's a great benefit for patients. And if you assume about a 50% relapse rate for those leaving treatment with buprenorphine, that's a very big benefit.
How do you handle the complexities of opioid addiction treatment when faced with the rise of fentanyl? In this episode of 'Addiction Medicine Journal Club', Dr. Sonya Del Tredici and Dr. John Keenan dive into the pressing issue of prescribing 24 mg of buprenorphine daily. They dissect a recent JAMA Network Open study comparing 16 to 24 milligrams of buprenorphine, offering valuable insights for addiction medicine practitioners. The discussion doesn't stop there.
The hosts also explore the implications of Rite Aid's bankruptcy, linked to slumping sales and opioid lawsuits, and the FDA's bold move to ban menthol cigarettes and flavored cigars. These topics highlight the ever-changing landscape of addiction treatment and regulation. Whether you're a healthcare professional or someone keen on understanding the latest in addiction medicine, this episode is packed with crucial information.
Tune in for an engaging conversation that sheds light on the benefits and challenges of higher buprenorphine doses in today's opioid crisis.